1. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status;Gangat;Journal of Clinical Oncology,2011
2. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis;Pardanani;Leukemia,2013a
3. Results OF a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF);Pardanani;Blood (ASH Annual Meeting Abstracts),2013b
4. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis;Shah;Blood (ASH Annual Meeting Abstracts),2008
5. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT);Tefferi;Blood,2006